J Cancer 2018; 9(16):2938-2945. doi:10.7150/jca.22532
PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer
1. Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China
2. Lee's Pharmaceutical (Hong Kong) Limited, Hong Kong 999077, P.R. China
3. Zhaoke Pharmaceutical (Hefei) Company Limited, Hefei City, Anhui 230088, P.R. China
* Ying Meng, Huyi Liang and Jianguo Hu contribute equally to this article.
Programmed death-ligand 1 (PD-L1) has been reported to be expressed in many types of tumor cells, and bind to PD-1 on T lymphocytes to inhibit immune response. Immunologic checkpoint blockade with antibodies that target the PD1/PD-L1 pathway has demonstrated to have impressive antitumor effects on many malignancies. However, the significance of PD1/PD-L1 pathway in cervical cancer remains unclear. Here we studied PD-L1, PD-1, CD8 and HPV expression in cervical cancer and normal cervix by immunohistochemical staining. Our results showed that there was more frequently positive for PD-L1, PD-1 and CD8 in cervical cancer tissues compared to normal tissues, especially those strongly stained HPV. Additionally, PD-L1, PD-1 and CD8 were more frequently stained in tissues from advanced tumor and tumor with lymphoid nodes or vascular invasion respectively. Tissues from patients with chemotherapy history had over expression of PD-L1 in tumor cells and more PD-1 and CD8 in stromal mononuclear cells, which were identified as tumor infiltrated lymphocytes (TILs). These findings point to a key role of PD-L1 in immune escape of cervical cancer, and provide a rationale for therapeutic targeting of the PD-1/PD-L1 pathway.
Keywords: PD-L1, HPV, cervical cancer, chemotherapy, CD8.
Meng Y, Liang H, Hu J, Liu S, Hao X, Wong MSK, Li X, Hu L. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer. J Cancer 2018; 9(16):2938-2945. doi:10.7150/jca.22532. Available from http://www.jcancer.org/v09p2938.htm